Literature DB >> 3902204

Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation.

L Boros, C Chuang, F O Butler, J M Bennett.   

Abstract

Every adult acute nonlymphocytic leukemia patient in Rochester, New York seen from January 1975 to January 1982 was studied. Fifty percent of the patients did not receive combination chemotherapy. Among those who did, there was a significant selection bias toward placing patients with better prognostic features on protocol. Protocol patients were also treated with higher doses of chemotherapy than nonprotocol patients. However, these factors did not completely explain the significantly better complete response (CR) rate and survival among protocol patients. Eastern Cooperative Oncology Group (ECOG) participation remained an independent variable associated with a better outcome. An improvement in CR rate was seen during the 7-year period studied as compared to that seen between 1965 and 1974. The study provided evidence that the availability and use of ECOG protocols was a positive factor in the improvement of leukemia treatment in Rochester.

Entities:  

Mesh:

Year:  1985        PMID: 3902204     DOI: 10.1002/1097-0142(19851101)56:9<2161::aid-cncr2820560904>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Low dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromes.

Authors:  M Murray; P Sarsfield; E Lawlor; S R McCann
Journal:  Ir J Med Sci       Date:  1988-07       Impact factor: 1.568

2.  The breast cancer research scandal: addressing the issues.

Authors:  C Weijer
Journal:  CMAJ       Date:  1995-04-15       Impact factor: 8.262

3.  Comparison of survival outcomes among cancer patients treated in and out of clinical trials.

Authors:  Joseph M Unger; William E Barlow; Diane P Martin; Scott D Ramsey; Michael Leblanc; Ruth Etzioni; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

4.  Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden.

Authors:  M Aström; L Bodin; I Nilsson; U Tidefelt
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

Review 5.  Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.

Authors:  Gunn Elisabeth Vist; Dianne Bryant; Lyndsay Somerville; Trevor Birminghem; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

6.  Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; G Ucci; R Luoni; S Brugnatelli; O Mora; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; F Alberio
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

7.  Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer: a qualitative study.

Authors:  Guek Eng Lee; Mandy Ow; Desiree Lie; Rebecca Dent
Journal:  BMC Womens Health       Date:  2016-07-22       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.